ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2155 entries already.
Entries by Thomas Gabrielczyk
Transgene’s licenced oncolytic virus fails in Phase III
SillaJen, the licensor for French immunoncology specialist Transgene SA, has stopped enrolment into the Phase III Phocus trial after an Independent Data Review Comittee predicted the study endpoint won’t be met.
Wellington Partners launch €210m Life Sciences fund
Wellington Partners has closed its largest Life Sciences Fund ever. The VC specialist outperformed its intial target of raising €120m to €150m and closed at €210m.
Alizé Pharma 3 bags largest EU financing so far
Venture Captital specialist LSP led a €67m Series A financing in peptide developer Alizé Pharma 3.
Better TNF? receptor blockers on the horizon
Two research teams have unraveled the complex dynamics of TNF? receptor signaling and have identified compounds that may be safer than current treatments.
AgroSavfe raises €35m in Series C financing
Plant protection specialist AgroSavfe will use the funds of a €35m Series C financing to push the development, registration and commercial scale production of its biofungicides and bio-insecticide.
European Commission approves ten GMOs
The European Commission has authorised ten genetically modified products.
Zambon heading to US market with €500m acquisition
Zambon is set to acquire respiratory company Breath Therapeutics for up to €500m to complement its respiratory pipeline and get access to the US market.
Gut microbiome boosts muscle strength
Swedish researchers have demonstrated that the gut microbiome can significantly affect the proper development and strength of skeletal muscle.
3P Pharma finds new major investor
Pamplona-based CDMO 3P Biopharmaceuticals (3P) has announced Keensight Capital as its new major investor after previous major investor Infarco is refocussing on international expansion. By providing 3P with leap in terms of capacity, equipment, technology, and talent, Keensight is expected to consolidate 3P’s position as one of few mid-sized CDMOs on the international market that offers commercial manufacturing capabilities.
"We are extremely enthusiastic to work with Keensight Capita at such a crucial moment for our industry," said Dámaso Molero, CEO of 3P Biopharmaceuticals. "With their global footprint and their expertise inthe biologics field, I am highly confident that Keensight team will help us reach significant milestones in the coming years.
3P experienced a 23% annual revenue growth over the past 4 years, 10% above the rate the biological CDMO market is to grow from 2018-2022. The fully integrated specialist in process development and GMP-compliant manufacturing biologics and cell therapy products is further being funded by Sodena, the financial business development instrument of the Government of Navarra.